Intensive care medicine in 2050: NEWS for hemodynamic monitoring
- 2.1k Downloads
For decades, the hemodynamic assessment of critically ill patients relied almost exclusively on invasive dilution techniques and on echocardiography evaluations performed with cumbersome devices. Things changed dramatically over the last decade with the development of multiple less invasive cardiac output monitoring techniques and the metamorphosis of ultrasound devices. The continuous acceleration of hardware and software innovations makes it impossible to accurately predict what hemodynamic monitoring will be like 33 years from now. However, key trends can be envisioned and are summarized below using the acronym “NEWS”.
N for non-invasive techniques
KeywordsElectrical Impedance Tomography Hemodynamic Monitoring Pulse Pressure Variation Multiple Sensor Wearable Sensor
Compliance with ethical standards
Conflicts of interest
FM has been a consultant to Pulsion Medical Systems and UP-MED, and an employee of Edwards Lifesciences (VP Global Medical Strategy). He is co-inventor of nine patents owned by Pulsion, UP-MED, and Edwards, but does not receive any royalties. He is the founder and managing director of MiCo Sarl, a Swiss consulting firm providing services to medtech companies and digital health startups. MRP has been a consultant to Cheetah Medical, Edwards LifeSciences, Exostat, LiDCO, and Masimo, is the co-founder of Critica, and the inventor of US patent “A system and method of determining susceptibility to cardiorespiratory insufficiency” owned by the University of Pittsburgh; and co-inventor of US patent “A method for automated determination of artifact and real alerts in clinical monitoring data,” owned jointly by Carnegie-Melon University and the University of Pittsburgh. JLV has no conflict of interest to declare.